Amarin Defends VASCEPA’s Role Amid New Triglyceride Treatment Options
Event summary
- Amarin reaffirms VASCEPA’s role in triglyceride treatment as FDA approves new injectable APOC3 therapies for severe hypertriglyceridemia (sHTG).
- VASCEPA offers a 33% median reduction in TG levels without increasing LDL cholesterol, compared to other agents.
- Annual wholesale acquisition cost for VASCEPA is $4,200 per patient, significantly lower than the $40,000 cost of new APOC3 therapies.
- VASCEPA has been prescribed over 30 million times globally and remains the only FDA-approved therapy proven to reduce cardiovascular event risk by 25%.
- The 2026 ACC/AHA Dyslipidemia Guideline reaffirms VASCEPA’s role in managing elevated triglycerides.
The big picture
Amarin’s defense of VASCEPA comes as the cardiovascular treatment landscape evolves with the introduction of high-cost injectable APOC3 therapies. The company emphasizes VASCEPA’s proven efficacy, lower cost, and broad accessibility as key differentiators in a market where cost and coverage may influence patient access to new treatments. The reaffirmation of VASCEPA’s role by leading medical societies underscores its continued relevance in managing elevated triglycerides and reducing cardiovascular risk.
What we're watching
- Market Positioning
- How Amarin will position VASCEPA against higher-cost APOC3 therapies in the sHTG treatment landscape.
- Payer Dynamics
- Whether payers and managed care organizations will prioritize cost-effective treatments like VASCEPA over premium-priced alternatives.
- Clinical Adoption
- The pace at which new guidelines and clinical evidence will drive adoption of VASCEPA in broader patient populations.
Related topics